secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2022-02-14T23:59:59+00:00
Accession:  0001654954-22-001575
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports Q1 net loss of $4.4M; Health Canada approves Phase 3 design for EB05
--------------------------------------------------------------------------------

- Net loss $4.38M ($0.33/share) vs $2.64M ($0.26/share) a year ago; operating expenses up $2.55M.
- R&D expenses increased $2.57M to $3.95M, primarily due to external clinical study and drug product costs.
- Health Canada approved Phase 3 design of Phase 2/3 study for EB05 as rescue therapy for ARDS.
- Phase 2b chronic Allergic Contact Dermatitis study reached enrollment milestone; pace returning to pre-pandemic.
- Working capital $8.14M; cash $5.88M; subsequent equity issuance raised ~$1.19M from RBC Capital Markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422001575/0001654954-22-001575-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422001575/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-001575

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer